Goodwin Procter LLP advised CRISPR Therapeutics AG on the deal. CRISPR Therapeutics completed $517.5 million follow-on offering, including the full exercise of the underwriters’ option to purchase additional shares,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now